Key Step Toward Mass Production of Artificial Blood Achieved

Scientists from the University of Konstanz and Queen Mary University of London have made a significant breakthrough in the development of large-scale artificial blood production. In a study published in Science Signaling, the researchers identified the crucial role of the chemokine CXCL12 in the final stage of red blood cell maturation—a process in which precursor cells expel their nuclei to become fully functional erythrocytes.

Under natural conditions, this transformation takes place in the bone marrow, where stem cells differentiate into erythroblasts and then into mature red blood cells. The expulsion of the nucleus allows the cells to become more compact and carry more hemoglobin. By introducing CXCL12 at the right moment in laboratory settings, scientists were able to trigger this process more efficiently, offering new possibilities for optimizing artificial blood technologies.

Currently, artificial red blood cells are primarily produced from stem cells derived from umbilical cord blood or bone marrow, both of which are limited resources. While reprogramming regular cells into stem cells is already possible, the efficiency of nuclear expulsion in such cases remains below 40%. The addition of CXCL12 could significantly improve this outcome.

This discovery holds promise not only for addressing shortages in donor blood but also for producing rare blood types and generating patient-specific blood for treating severe diseases.

Earlier, clinical trials began in Japan for a universal form of artificial blood developed using recycled donor hemoglobin.

Follow NEWS.am Medicine on Facebook and Twitter